Further insight into the effects of semaglutide in patients who receive background SGLT2 inhibitors will be provided by the STEP-HFpEF DM trial, which includes a greater proportion (32%) of patients taking these agents12. The gene discussed is SLC5A2; the disease is diabetes mellitus.